表紙
市場調査レポート

急性骨髄性白血病(AML):機会分析・予測

OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024

発行 GlobalData 商品コード 279162
出版日 ページ情報 英文 326 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
急性骨髄性白血病(AML):機会分析・予測 OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024
出版日: 2015年12月01日 ページ情報: 英文 326 Pages
概要

当レポートでは、急性骨髄性白血病(AML)市場について調査し、疫学、病因、病態生理学、症状、診断および疾病管理を含めたAMLの概要、AML治療市場の収益、AML治療市場における競合企業の戦略的評価、市場特徴付け、アンメットニーズ、R&D戦略および臨床設計、パイプライン分析、世界のAML治療市場における現在・将来の市場競合分析などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理学
  • 症状

第4章 疫学

  • リスク因子・併存疾患
  • 世界の動向
  • 予測手法
  • 急性骨髄性白血病(AML)の疫学的予測
  • 議論

第5章 疾病管理

  • 診断
  • 応答基準
  • 一般的治療の概要
  • 造血幹細胞移植
  • 残存疾患のモニタリング
  • APL

第6章 現在の治療オプション

  • 概要
  • 製品プロファイル:主要ブランド

第7章 アンメットニーズの評価・機会分析

  • 概要
  • アンメットニーズの分析
  • 機会分析

第8章 R&D戦略

  • 概要
  • 治験設計

第9章 パイプライン評価

  • 概要
  • 臨床開発における有望な薬剤
  • 革新的な期段階のアプローチ

第10章 パイプライン評価分析

  • 主要パイプライン薬剤の臨床ベンチマーク
  • 主要パイプライン薬剤の商業ベンチマーク
  • 競合評価
  • 総収入の5カ年予測

第11章 付録

  • 参考資料
  • 略語
  • 調査手法
  • 予測手法
  • 医師・専門家
  • 著者について
  • GlobalDataについて
  • 免責事項

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC051POA

Acute myeloid (myelogenous, myelocytic) leukemia (AML) is a rapidly progressing blood cancer with an extremely poor overall prognosis. AML predominantly affects the elderly population and this subgroup of patients has an exceptionally high level of unmet needs. GlobalData estimates the 2014 sales for AML at approximately $342 million across the 7MM covered in this report. The market will increase by almost three-fold over the forecast period, reaching $932 million in 2024 at a CAGR of 10.5%. This growth will be driven by an increase in incident cases of AML as well as the approval and uptake of premium-priced products, such as FLT3 kinase inhibitors (quizartinib and midostaurin), a PI3 kinase inhibitor (volasertib) and new formulations of existing chemotherapies such as Vyxeos (CPX-351), guadecitabine and CC-486. GlobalData expects, by the end of the forecast period, new branded therapies Vyxeos, volasertib and CC-486 will dominate the market along with generic azacitidine. The AML pipeline is weak in terms of efficacy; however, GlobalData expects none of these drugs to have a major impact on the overall AML market. The challenge for new entrants into the AML market is to meet the critically high unmet needs of AML patients and improve overall survival. One of the opportunities for the companies is to work cooperatively to develop therapies that work in combination with chemotherapy backbone.

Highlights

Key Questions Answered

  • For over forty years, there has been no major advances in the treatment for AML. The AML space is filled with excitement because the first targeted FLT3 kinase inhibitor therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on AML sales?
  • With the unmet needs of AML patients remaining critically high, what R&D strategies and opportunities are being used by drug makers to remain competitive?
  • The survival of patients with AML remains dismal, especially for those who do not respond to first-line chemotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the AML market?

Key Findings

  • One of the main drivers in the expansion of the AML market will be the launch of premium-priced targeted therapies (FLT3 kinase inhibitors, PI3 kinase inhibitor and reformulations of chemotherapy drugs). for patients with extremely high unmet needs, both the elderly and refractory/relapsed population. These drugs will gradually be used in combination with or replace cheaper, generic, cytarabine-based chemotherapy regimens.
  • Another driver will be the few players in the AML market, and that current therapies are largely considered to be ineffective. Therefore, there is ample room for new market entrants. A major driver will also be that a growing incident elderly AML population, particularly in the US, will increase the number of treatable AML patients.
  • Companies are focusing on the development of combination therapies, trying to improve the complete remission rate and duration of remission.
  • One of the largest unmet needs is a need for efficacious treatment options for elderly AML patients. The majority of AML patients do not have FLT3 mutations, and are therefore ineligible for FLT3 inhibitor treatments. Other unmet needs include therapies for refractory/relapsed disease.

Scope

  • Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), forecast from 2014 to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global AML therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Cytogenetic and Molecular Abnormalities
  • 3.2. Prognosis
  • 3.3. Quality of Life
  • 3.4. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. Increased age is associated with increased risk and worsened prognosis
    • 4.2.2. Smoking increases the risk of M2 AML
    • 4.2.3. APL is relatively common among Spanish and Italian origins
    • 4.2.4. Chemotherapy and radiation therapy increases the risk of AML
    • 4.2.5. Benzene increases risk of AML
  • 4.3. Global Trends
    • 4.3.1. Incidence
    • 4.3.2. Survival and Prevalence
    • 4.3.3. Subtypes and Mutations
    • 4.3.4. Risk Groups
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources not Used
  • 4.5. Epidemiological Forecast for Acute Myeloid Leukemia (2014-2024)
    • 4.5.1. Adjusted Diagnosed Incident Cases of AML
    • 4.5.2. Adjusted Diagnosed Incident Cases of AML by Age
    • 4.5.3. Adjusted Diagnosed Incident Cases of AML by Sex
    • 4.5.4. Age-Standardized Incidence of AML
    • 4.5.5. APL and MDS/tAML
    • 4.5.6. APL and MDS/tAML by Age
    • 4.5.7. Diagnosed Incident Cases of AML with FLT3 Mutations
    • 4.5.8. Diagnosed Incident Cases of AML by Risk Group Classifications
    • 4.5.9. Five-Year Diagnosed Prevalent Cases of AML
    • 4.5.10. Five-Year Diagnosed Prevalent Cases of AML by Age
    • 4.5.11. Five-Year Diagnosed Prevalent Cases of APL and MDS/tAML
    • 4.5.12. Five-Year Diagnosed Prevalent Cases of APL and MDS/tAML by Age
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
  • 5.2. Response Criteria and Outcome Measures
  • 5.3. General Treatment Overview
    • 5.3.1. Younger AML Patients
    • 5.3.2. Older AML Patients
  • 5.4. Hematopoietic Stem Cell Transplant
  • 5.5. Monitoring for Residual Disease
  • 5.6. Acute Promyelocytic Leukemia

6. Current Treatment Options

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Cytarabine
    • 6.2.2. Dacogen (decitabine)
    • 6.2.3. Vidaza (azacitidine)
    • 6.2.4. Mylotarg (gemtuzumab ozogamicin)
    • 6.2.5. Other Therapeutic Agents for AML

7. Unmet Needs Assessment and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Unmet Needs Analysis
    • 7.2.1. Unmet Need: Therapies that Prolong the OS of AML Patients
    • 7.2.2. Unmet Need: Elimination of Residual Disease
    • 7.2.3. Unmet Need: Therapies that Achieve Durable CR in AML Patients
    • 7.2.4. Unmet Need: Safety
    • 7.2.5. Unmet Need: Maintenance Therapies
    • 7.2.6. Unmet Need: Improvement in Guidelines Directing the Optimum Course of Therapy
    • 7.2.7. Unmet Need: Therapies with More Convenient Administration and Dosing Regimens
  • 7.3. Opportunity Analysis
    • 7.3.1. Opportunity: Targeting Minimal Residual Disease (Leukemic Stem Cells)
    • 7.3.2. Opportunity: Targeting Driver Molecular Mutations with Combination Therapy
    • 7.3.3. Opportunity: Development of Immunotherapies for AML
    • 7.3.4. Opportunity: Use of Differentiation Agents in AML
    • 7.3.5. Opportunity: Development of Oral Maintenance Therapies
    • 7.3.6. Opportunity: Development of Safer Conditioning Regimens pre-HSCT

8. R&D Strategies

  • 8.1. Overview
    • 8.1.1. Targeting Multiple Patient Segments
    • 8.1.2. Developing Novel Drugs in Combination with Established Therapies
    • 8.1.3. Targeting Elderly AML Patients
    • 8.1.4. Investigating New Targets Involved in the Pathogenesis of AML
    • 8.1.5. Alliances Between Academic Groups and Pharmaceutical Companies
  • 8.2. Clinical Trial Design
    • 8.2.1. Selection of the Appropriate Efficacy Endpoints to Support Regulatory Approval
    • 8.2.2. Selection of Active Comparator
    • 8.2.3. Randomization and Stratification of Patients
    • 8.2.4. Current Clinical Trial Design
    • 8.2.5. Future Trends in Clinical Trial Design

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Drugs in Late-Stage Clinical Development
    • 9.2.1. CC-486(oral azacitidine)
    • 9.2.2. Guadecitabine (SGI-110)
    • 9.2.3. Vyxeos (CPX-351)
    • 9.2.4. Qinprezo (vosaroxin)
    • 9.2.5. Sapacitabine (CYC682)
    • 9.2.6. Gilteritinib (ASP2215)
    • 9.2.7. Midostaurin (PKC412)
    • 9.2.8. Quizartinib (AC220)
    • 9.2.9. Volasertib (BI 6727)
    • 9.2.10. Ganetespib (STA-9090)
  • 9.3. Innovative Early-Stage Approaches
    • 9.3.1. Biologic-Targeted Therapies
    • 9.3.2. Immunotherapies
    • 9.3.3. Epigenetic Approaches
    • 9.3.4. Stem Cell Therapies and other Cell-Based Regimens

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmark of Key Pipeline Drugs
  • 10.2. Commercial Benchmark of Key Pipeline Drugs
  • 10.3. Competitive Assessment
  • 10.4. Top-Line -Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU
    • 10.4.3. Japan

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed AML Patients
    • 11.4.2. Percent Drug-treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. General Forecast Assumptions
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
    • 11.5.1. Primary Research - Prescriber Survey
  • 11.6. About the Authors
    • 11.6.1. Authors
    • 11.6.2. Epidemiologist
    • 11.6.3. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Classification of AML Subtypes - WHO System
  • Table 2: Classification of AML Subtypes - FAB System
  • Table 3: Common Cytogenetic Abnormalities in AML
  • Table 4: Symptoms of AML
  • Table 5: Risk Factors for AML in Adults
  • Table 6: Incidence of AML per 100,000 Population in Japan, 1993-2002, All Ages
  • Table 7: Estimated Frequencies of Cytogenetic Abnormalities in AML
  • Table 8: Risk Group Classification Guidelines
  • Table 9: 7MM, Sources of AML Diagnosed Incidence
  • Table 10: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 11: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, N (Row %), 2014
  • Table 12: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, N (Row %), 2014
  • Table 13: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 14: 7MM, Diagnosed Incident Cases of MDS/tAML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 15: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N (Row % in Each Subtype), 2014
  • Table 16: 7MM, Diagnosed Incident Cases of AML with FLT3 Mutations, Both Sexes, Ages ≥20 Years, N, Selected Years 2014-2024
  • Table 17: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N (Row %), 2014
  • Table 18: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N (Row %), 2014
  • Table 19: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 20: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, N (Row %), 2014
  • Table 21: 7MM, Five-Year Diagnosed Prevalent Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 22: 7MM, Five-Year Diagnosed Prevalent Cases of MDS/tAML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024
  • Table 23: 7MM, Five-Year Diagnosed Prevalent Cases of AML Subtypes by Age, Both Sexes, N (Row %), 2014
  • Table 24: Types of Responses - AML
  • Table 25: Outcome Measures in AML
  • Table 26: Induction and Consolidation Regimens for APL by Patient Risk Group
  • Table 27: Leading Treatments for AML
  • Table 28: Product Profile - Cytarabine (generic)
  • Table 29: Cytarabine SWOT Analysis
  • Table 30: Product Profile - Dacogen
  • Table 31: Efficacy of Dacogen vs Physicians' Choice of Treatment (DACO-016 Trial; NCT00260832)
  • Table 32: Safety of Dacogen (decitabine) in AML Patients (DACO-016 Trial; NCT00260832)
  • Table 33: Dacogen SWOT Analysis
  • Table 34: Product Profile - Vidaza
  • Table 35: Efficacy of Vidaza vs Conventional Care Regimens in Newly Diagnosed or Secondary Elderly AML Patients with >30% Blasts (NCT01074047; AML-001)
  • Table 36: Safety of Vidaza (azacitidine) in Newly Diagnosed or Secondary Elderly AML Patients with >30% Blasts (NCT01074047; AML-001)
  • Table 37: Vidaza SWOT Analysis
  • Table 38: Product Profile - Mylotarg (Gemtuzumab Ozogamicin [GO])
  • Table 39: Efficacy of Mylotarg vs Best Supportive Care in Previously Untreated Elderly AML Patients (NCT00091234; AML-19)
  • Table 40: Safety of Mylotarg in Previously Untreated Elderly AML Patients (NCT00091234; AML-19)
  • Table 41: Mylotarg SWOT Analysis
  • Table 42: Other Therapeutic Agents Prescribed for AML
  • Table 43: Overall Unmet Needs in AML - Current Level of Attainment
  • Table 44: Design of Current Phase III Trials in AML
  • Table 45: AML - Late-Stage Pipeline, 2015
  • Table 46: Product Profile - CC-486
  • Table 47: Efficacy of CC-486 in AML Patients
  • Table 48: Efficacy of CC-486 Extended Dosing Schedules in WHO-defined RAEB-1 or RAEB-2 MDS (Ad-hoc analysis of two ongoing Phase I/II studies)
  • Table 49: Safety of CC-486 in AML Patients
  • Table 50: CC-486 SWOT Analysis
  • Table 51: Global Sales Forecast ($m) for CC-486, 2014-2024
  • Table 52: Product Profile - Guadecitabine
  • Table 53: Efficacy of Guadecitabine in Previously Untreated Elderly AML Patients (Trial NCT02348489)
  • Table 54: Efficacy of Guadecitabine in Elderly Patients Ineligible for Intensive Chemotherapy (Trial NCT01261312)
  • Table 55: Safety of Guadecitabine in Elderly Patients Ineligible for Intensive Chemotherapy
  • Table 56: Safety of Guadecitabine in Previously Untreated Elderly AML Patients (Trial NCT02348489)
  • Table 57: Safety of Guadecitabine in Refractory/Relapsed AML Patients
  • Table 58: Guadecitabine SWOT Analysis
  • Table 59: Global Sales Forecast ($m) for Guadecitabine (SGI-110), 2014-2024
  • Table 60: Product Profile - Vyxeos
  • Table 61: Efficacy of Vyxeos versus 7+3 Regimen in Patients Between 60 and 75 Years of Age with Newly Diagnosed AML (Trial NCT00788892)
  • Table 62: Efficacy of Vyxeos in AML Patients (18-65 years of age) in First Relapse (Trial NCT00822094)
  • Table 63: Safety of Vyxeos in AML Patients (18-65 years of age) in First Relapse (Trial NCT00822094)
  • Table 64: Vyxeos SWOT Analysis
  • Table 65: Global Sales Forecast ($m) for Vyxeos, 2014-2024
  • Table 66: Product Profile - Qinprezo
  • Table 67: Efficacy of Qinprezo in Refractory/Relapsed AML Patients of All Ages (Trial NCT01191801; VALOR)
  • Table 68: Safety of Qinprezo in Refractory/Relapsed AML Patients of All Ages (Trial NCT01191801; VALOR)
  • Table 69: Qinprezo SWOT Analysis
  • Table 70: Global Sales Forecast ($m) for Qinprezo, 2014-2024
  • Table 71: Product Profile - Sapacitabine
  • Table 72: Efficacy of Sapacitabine in Elderly Patients with Newly Diagnosed AML (>70 years) (Trial NCT01303796; SEAMLESS)
  • Table 73: Safety of Sapacitabine in Elderly Patients with Newly Diagnosed AML (Trial NCT01303796)
  • Table 74: Sapacitabine SWOT Analysis
  • Table 75: Global Sales Forecast ($m) for Sapacitabine, 2014-2024
  • Table 76: Product Profile - Gilteritinib
  • Table 77: Efficacy of Gilteritinib in Refractory/Relapsed AML Patients (Trial NCT02014558)
  • Table 78: Safety of Gilteritinib in Refractory/Relapsed AML Patients (Trial NCT02014558)
  • Table 79: Gilteritinib SWOT Analysis
  • Table 80: Global Sales Forecast ($m) for Gilteritinib, 2014-2024
  • Table 81: Product Profile - Midostaurin
  • Table 82: Efficacy of Midostaurin in Combination with Vidaza in Patients with AML/MDS (>65 years of age) (Trial NCT01202877)
  • Table 83: Safety of Midostaurin in Combination with Vidaza in Patients with AML/MDS (>65 years of age) (NCT01202877)
  • Table 84: Midostaurin SWOT Analysis
  • Table 85: Global Sales Forecast ($m) for Midostaurin, 2014-2024
  • Table 86: Product Profile - Quizartinib
  • Table 87: Efficacy of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients (Trial NCT01565668)
  • Table 88: Efficacy of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients as a Bridge to HSCT
  • Table 89: Safety of Quizartinib in FLT3-ITD(+) Refractory/Relapsed AML Patients (Trial NCT01565668)
  • Table 90: Quizartinib SWOT Analysis
  • Table 91: Global Sales Forecast ($m) for Quizartinib, 2014-2024
  • Table 92: Product Profile - Volasertib
  • Table 93: Efficacy of Volasertib with LDAC in Elderly AML Patients Ineligible for Intensive therapy (Trial NCT00804856)
  • Table 94: Safety of Volasertib with LDAC in Elderly AML Patients Ineligible for Intensive Therapy (Trial NCT00804856)
  • Table 95: Volasertib SWOT Analysis
  • Table 96: Global Sales Forecast ($m) for Volasertib, 2014-2024
  • Table 97: Product Profile - Ganetespib
  • Table 98: Ganetespib SWOT Analysis
  • Table 99: Global Sales Forecast ($m) for Ganetespib, 2014-2024
  • Table 100: Early-Stage Pipeline Products in AML
  • Table 101: Clinical Benchmark of Key Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML Patients (all ages >20 years)
  • Table 102: Clinical Benchmark of Key Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML Patients (all ages >20 years)
  • Table 103: Clinical Benchmark of Key Pipeline Drugs - Refractory/Relapsed AML Patients (all ages >20 years)
  • Table 104: Commercial Benchmark of Key Marketed and Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML patients (all ages >20 years)
  • Table 105: Commercial Benchmark of Key Pipeline Drugs - First-Line Therapies for Newly Diagnosed AML Patients (all ages >20 years)
  • Table 106: Commercial Benchmark of Key Pipeline Drugs - Relapsed/Refractory AML Patients (all ages >20 years)
  • Table 107: Global Top-Line Sales Forecasts ($m) for AML, 2014-2024
  • Table 108: Key Events Impacting Sales for AML in the US, 2014-2024
  • Table 109: Key Events Impacting Sales for AML in Japan, 2014-2024
  • Table 110: Key Events Impacting Sales for AML in the 5EU, 2014-2024
  • Table 111: AML Market in the US - Drivers and Barriers, 2014
  • Table 112: 5EU AML Market - Drivers and Barriers, 2014
  • Table 113: Japan AML Market - Drivers and Barriers, 2014
  • Table 114: Key Launch Dates
  • Table 115: Key Patent Expiries
  • Table 116: Average Body Weight, Height and Surface Area, Across the 7MM
  • Table 117: High-Prescribing Physicians Surveyed by Country

List of Figures

  • Figure 1: Comparison of Normal and Leukemia Blood Cell Differentiation
  • Figure 2: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 3: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, Ages ≥20 Years, N, 2014
  • Figure 4: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, Ages ≥20 Years, N, 2014
  • Figure 5: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages ≥20 Years, 2014
  • Figure 6: 7MM, Diagnosed Incident Cases of APL, and MDS/tAML, Both Sexes, Ages ≥20 Years, N, 2014 and 2024
  • Figure 7: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N, 2014
  • Figure 8: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N, 2014
  • Figure 9: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N, 2014
  • Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024
  • Figure 11: Dacogen's Development in AML
  • Figure 12: Vidaza's Development in AML
  • Figure 13: Mylotarg's Development in AML
  • Figure 14: CC-486's Development in AML
  • Figure 15: Guadecitabine's (SGI-110) Development in AML
  • Figure 16: Vyxeos' Development in AML
  • Figure 17: Qinprezo's (vosaroxin) Development in AML
  • Figure 18: Sapacitabine's Development in AML
  • Figure 19: Gilteritinib's (ASP2215) Development in AML
  • Figure 20: Midostaurin's (PKC412) Development in AML
  • Figure 21: Quizartinib's Development in AML
  • Figure 22: Volasertib's Development in AML
  • Figure 23: Ganetespib's Development in AML
  • Figure 24: Competitive Assessment of Late-Stage Pipeline Agents in AML, 2014-2024
  • Figure 25: Global Sales for AML by Region, 2014-2024
Back to Top